Qlaris Bio is developing therapeutics to treat serious and debilitating ophthalmic diseases. Patients with certain ophthalmic diseases suffer a progressive and permanent loss of vision over time, with glaucoma remaining a leading cause of preventable blindness worldwide. To address glaucoma, Qlaris is investigating new mechanisms of action driving glaucoma that can be targeted using therapies with a sustained duration of action to reduce the burden of eyedrops and to work independently from intraocular pressure-lowering drugs so that the optic nerve can be better protected. Qlaris’ lead program, QLS-111, has a unique vasodilatory mechanism of action and is now being progressed into clinical trials.

Qlaris Bio

Short description:

Drug notes:

Long description:

Jobs: